Novartis (NVS) said Wednesday new Cosentyx data from a late-stage trial in polymyalgia rheumatica showed a statistically significant, clinically meaningful difference in sustained remission rates against placebo and significant steroid sparing.

The effect of Cosentyx treatment was sustained through week 52, the company said, adding that the trial met all primary and secondary endpoints, and no new safety signals were identified.

Novartis said it has submitted Cosentyx for regulatory review in the US, EU, and Japan, with other filings expected to follow throughout 2026, it added.

Separately, Novartis Canada said it has reached an agreement with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Scemblix for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

Price: 143.53, Change: +0.05, Percent Change: +0.03